# Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

> **NCT02121795** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 668 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** FTC/TDF
- **DRUG:** F/TAF
- **DRUG:** Allowed third antiretroviral agent
- **DRUG:** FTC/TDF Placebo
- **DRUG:** F/TAF Placebo

## Key facts

- **NCT ID:** NCT02121795
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-06
- **Primary completion:** 2015-08-12
- **Final completion:** 2019-03-01
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2020-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02121795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02121795, "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02121795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*